# Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

> **NCT03801902** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Recurrent Lung Non-Small Cell Carcinoma
- Stage II Lung Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Unresectable Lung Non-Small Cell Carcinoma

## Interventions

- **RADIATION:** Accelerated Hypofractionated Radiation Therapy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **PROCEDURE:** Magnetic Resonance Imaging of the Brain with and without Contrast
- **BIOLOGICAL:** Monalizumab
- **BIOLOGICAL:** Oleclumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03801902
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-28
- **Primary completion:** 2021-10-26
- **Final completion:** 2025-09-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801902, "Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03801902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*